Bello Ridwan Opeyemi, Frew Shannon, Siddiqui Yusra, Minhas Rashid
School of Human Sciences, College of Science and Engineering, University of Derby, Derby DE22 1GB, UK.
Faculty of Health and Life Sciences, University of Exeter, Exeter EX4 4QJ, UK.
Muscles. 2023 Oct 12;2(4):338-352. doi: 10.3390/muscles2040026.
The heart is composed of muscle cells called cardiomyocytes, including a specialized population named pacemaker cells that form the cardiac conduction system (CCS), which is responsible for generating the action potential dictating heart contractions. Failure of the CCS system leads to cardiac arrhythmias, which require complicated therapies and often the surgical implantation of electrical pacemakers. However, recent research has focused on the development of novel therapies using biological pacemakers that aim to substitute electrical devices. While most signaling pathways and transcription factors involved in the development of the pacemaker cells are known, the upstream regulatory networks need to be predicted through computer-based databases, mathematical modeling, as well as the functional testing of the regulatory elements in vivo, indicating the need for further research. Here, we summarize the current knowledge about the vertebrate myocardial CCS system and the development of the pacemaker cells, as well as emphasize the areas of future research to clarify the regulation of muscle pacemaker cells and the ease of development of biological therapies.
心脏由称为心肌细胞的肌肉细胞组成,其中包括一群特殊的起搏细胞,这些细胞形成心脏传导系统(CCS),该系统负责产生决定心脏收缩的动作电位。CCS系统功能失调会导致心律失常,这需要复杂的治疗方法,通常还需要手术植入电子起搏器。然而,最近的研究集中在开发旨在替代电子设备的生物起搏器的新型疗法上。虽然已知大多数参与起搏细胞发育的信号通路和转录因子,但上游调控网络需要通过基于计算机的数据库、数学建模以及体内调控元件的功能测试来预测,这表明有必要进行进一步研究。在这里,我们总结了关于脊椎动物心肌CCS系统和起搏细胞发育的当前知识,并强调了未来研究的领域,以阐明肌肉起搏细胞的调控以及生物疗法开发的便利性。